Sodium fusidate in Gillain-Barré syndrome: a case report.
J Neurol Neurosurg Psychiatry
; 65(2): 266-8, 1998 Aug.
Article
en En
| MEDLINE
| ID: mdl-9703187
A patient with Guillain-Barré syndrome is reported on who responded favourably to a short course treatment with the novel immunosuppressant sodium fusidate (Fucidin), given at a daily dose of 1.5 g for one week. Along with prompt and clear cut clinical improvement, treatment with Fucidin was associated with a rapid decline in the blood concentrations of inflammatory cytokines presumably implicated in the pathogenesis of Guillain-Barré syndrome such as interleukin-2, interferon-gamma, and tumor necrosis factor-alpha. The ex vivo production of these cytokines was also markedly diminished compared with pretreatment values. Fucidin was well tolerated and no clinical or biochemical side effects were seen.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Polirradiculoneuropatía
/
Ácido Fusídico
/
Inmunosupresores
Límite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
J Neurol Neurosurg Psychiatry
Año:
1998
Tipo del documento:
Article
País de afiliación:
Italia
Pais de publicación:
Reino Unido